# Artelo Biosciences Provides Business Update Outlining Upcoming Milestones and Reports 2026 First Quarter Financial Results
Canonical URL: https://biopharmsignal.com/news/ARTL/artelo-biosciences-provides-business-update-outlining-upcoming-milestones-and-reports-2026-first-quarter-financial-results
Ticker: ARTL
Company: Artelo Biosciences
Source: Artelo Biosciences
Published: 2026-05-14 20:05 EST
Original Source URL: https://ir.artelobio.com
## Article Body
No article body is available yet.
## Recent Company News
- 2026-05-14 20:05 EST — [Artelo Biosciences Provides Business Update Outlining Upcoming Milestones and Reports 2026 First Quarter Financial Results](https://biopharmsignal.com/news/ARTL/artelo-biosciences-provides-business-update-outlining-upcoming-milestones-and-reports-2026-first-quarter-financial-results) — Source: Artelo Biosciences
- 2026-04-28 12:25 EST — [Artelo Biosciences Announces Strategic Collaboration with Artificial Intelligence (AI) Leader ScienceMachine Highlighting New Expansion Opportunities and Insights for FABP5 Inhibitor Development](https://biopharmsignal.com/news/ARTL/artelo-biosciences-announces-strategic-collaboration-with-artificial-intelligence-ai-leader-sciencemachine-highlighting-new-expansion-opportunities-and-insights-for-fabp5-inhibitor-development) — Source: Artelo Biosciences
- 2026-04-20 11:50 EST — [Artelo Announces Peer-Reviewed Publication Supporting its FABP5 Inhibitor ART26.12 as a Novel Pain Treatment with a Potentially First-in-Class Profile](https://biopharmsignal.com/news/ARTL/artelo-announces-peer-reviewed-publication-supporting-its-fabp5-inhibitor-art26-12-as-a-novel-pain-treatment-with-a-potentially-first-in-class-profile) — Source: Artelo Biosciences
- 2026-04-07 11:50 EST — [Artelo Biosciences Regains Compliance with Nasdaq Listing Requirements](https://biopharmsignal.com/news/ARTL/artelo-biosciences-regains-compliance-with-nasdaq-listing-requirements) — Source: Artelo Biosciences
- 2026-03-30 20:46 EST — [Artelo Biosciences Announces Closing of $11.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules](https://biopharmsignal.com/news/ARTL/artelo-biosciences-announces-closing-of-11-0-million-private-placement-priced-at-the-market-under-nasdaq-rules) — Source: Artelo Biosciences
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)